导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.62% | 2859/4773 |
| 近一周 | -1.21% | 1815/5465 |
| 近一月 | -1.03% | 996/5421 |
| 近一季 | 0.19% | 966/5231 |
| 近半年 | 0.28% | 1329/4920 |
| 近一年 | 1.97% | 2379/4394 |
| 近两年 | 37.52% | 2006/2954 |
| 近三年 | 25.30% | 1298/2253 |
| 成立以来 | 33.97% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.78% 3941/4961 |
7.31% 2726/5312 |
- - |
- - |
| 2025 | 16.16% 2480/4813 |
-0.43% 2246/3635 |
2.92% 1271/4076 |
10.83% 3237/4524 |
2.28% 1013/4813 |
| 2024 | 17.54% 678/3463 |
3.54% 549/2808 |
0.01% 663/3014 |
16.09% 1538/3129 |
-2.22% 2004/3463 |
| 2023 | -7.98% 969/2656 |
0.87% 1678/2280 |
-4.14% 1071/2385 |
1.74% 282/2515 |
-6.46% 1785/2655 |
| 2022 | -16.13% 453/2207 |
-11.00% 471/1919 |
6.27% 735/2016 |
-12.71% 765/2113 |
1.57% 1218/2208 |
| 2021 | -6.48% 1009/1822 |
-2.48% 653/1255 |
0.52% 1096/1330 |
-6.59% 963/1466 |
2.15% 685/1822 |
| 2020 | 24.91% 626/1250 |
-10.48% 783/1028 |
10.58% 762/1067 |
12.10% 405/1164 |
12.56% 453/1184 |
| 2019 | 35.01% 384/1092 |
21.89% 589/739 |
4.29% 31/788 |
0.64% 494/850 |
5.53% 706/918 |
| 2018 | -17.25% 126/834 |
- - |
-7.12% 145/631 |
6.12% 52/660 |
-11.46% 296/682 |
| 2017 | 27.73% 84/714 |
- - |
- - |
- - |
- - |
| 2016 | -3.61% 145/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 博时上证50ETF联接A VS. 长安沪深300非周期A(740101) |